Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus.

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Abstract Text:

Pesach Segal,Haskel E Eliahou,Dieter Petzinna,Dieter Neuser,Andreas ,Manfred Spengler,

OBJECTIVE: The aim of the study was to investigate the efficacy and tolerability of long-term acarbose therapy in type 2 diabetic patients. STUDY DESIGN: In this double-blind, single-centre group comparison, patients were randomised to receive either acarbose or matching placebo, in addition to their regular antidiabetic therapy, over a period of 78 weeks. Eligibility for inclusion in the efficacy evaluation included a study duration of >/=510 days. METHODS: The primary efficacy parameter was the change in glycosylated haemoglobin (HbA(1)) from baseline to end of study. Secondary variables included changes in blood glucose and lipid parameters, as well as signs of retinopathy and nephropathy. PATIENTS: A total of 139 patients were assessed for safety and 88 patients (44 in each treatment group) were included in the efficacy analysis. Patients were generally overweight and the majority had previously been treated with sulphonylureas. RESULTS: Acarbose significantly improved fasting and 1-hour postprandial blood glucose levels compared with placebo (p = 0.039 and 0.009), and improvements in HbA(1) with acarbose versus placebo fell just short of significance (p = 0.057). There were no differences between treatments in changes in microvascular complications, but blood pressure improved with acarbose treatment. Two patients in the acarbose group experienced elevated liver enzyme levels. Generally, acarbose had a good safety profile and was well tolerated. CONCLUSION: Long-term treatment with acarbose was safe and efficacious in patients with type 2 diabetes mellitus that was insufficiently controlled by other oral antidiabetics.

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Publishing Authors By Initials

P Segal,HE Eliahou,D Petzinna,D Neuser,A ,M Spengler,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical drug investigation

VOLUME: 25

Page Numbers: 589-95

Journal Abbreviation:

ISSN: 1173-2563

DAY: 29

MONTH: 05

YEAR: 2005

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9504817

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus.

AFFILIATION: Diabetes and Lipid Metabolism Unit, Sheba Medical Center, Tel-Hashomer, and Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Drug Investig

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus Related Publications

• A cancer risk assessment of inner-city teenagers living in New York City and Los Angeles.
• Alternaria measures in inner-city, low-income housing by immunoassay and culture-based analysis.
• Ambulatory care survey--surprising and revealing.
• Aurora-C-T191D is a hyperactive Aurora-C mutant.
• Course and therapy of acute liver failure.
• Determinants of allergen concentrations in apartments of asthmatic children living in public housing.
• Effect of respiratory muscle endurance training on respiratory sensations, respiratory control and exercise performance A 15-year experience.
• Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
• Efficacy of integrated pest management in reducing cockroach allergen concentrations in urban public housing.
• Expiratory muscle fatigue impairs exercise performance.
• Factors influencing assignment of patients to compulsory admission.
• Hepatitis C Virus-Induced Secretion of Inflammatory Chemokines Preferentially Recruits NKG2A(+)CD8(+) T Cells.
• Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma.
• Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
• Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus.
• Modeling time-location patterns of inner-city high school students in New York and Los Angeles using a longitudinal approach with generalized estimating equations.
• Pesticide loadings of select organophosphate and pyrethroid pesticides in urban public housing.
• Prenatal and postnatal tobacco smoke exposure and respiratory health in Russian children.
• Respiratory control, respiratory sensations and cycling endurance after respiratory muscle endurance training.
• The toxic release inventory: fact or fiction? A case study of the primary aluminum industry.
• The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
• Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain.
• [Chromosome abnormalities in paraproteinemia with special reference to the idiopathic forms]
• [Interferons as therapy in viral hepatitis: are promises kept?]
• [Method of testing anorexigenic substances.]
• [New x-ray vehicle of the army medical service.]
• [Not Available.]
• [Surgical suture material and catgut testing.]
• [The influence of adrenalin on the blood content of adrenal cortex hormone.]
• [The treatment of bacterial infections with gamma-globulins.]